Business Context and Reporting Period
This Form 8-K is a current report filed by MRI Interventions, Inc. (not Clearpoint Neuro, Inc.) on January 25, 2013. The filing reports the completion of a private placement financing transaction previously announced by the Company.
Key Financial Metrics
The filing details a capital raise event rather than operational financial performance. Key figures include:
- Gross Proceeds: Approximately $11.0 million.
- Transaction Costs: Approximately $1.1 million in placement agents' fees and estimated offering expenses.
- Securities Issued: 9,201,684 shares of common stock and warrants to purchase up to 4,600,842 shares.
- Warrant Terms: Exercise price of $1.75 per share; exercisable until January 25, 2018.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the increase in equity capital and the issuance of new securities:
- Completion of the sale of 9,201,684 shares of common stock to accredited investors.
- Issuance of warrants covering 4,600,842 shares.
- Execution of a Registration Rights Agreement requiring the filing of a registration statement within 30 days.
Outlook, Risks, and Contingencies
Management Commentary and Obligations:
- The Company intends to file a Form D in accordance with Regulation D.
- The Company is obligated to file a Registration Statement with the SEC within 30 calendar days of the closing date.
- The Company must use best efforts to have the Registration Statement declared effective as soon as practicable.
Risks and Contingencies:
- Liquidated Damages: If the Registration Statement is not filed by the deadline, not declared effective by the 75th day (or 105th day if reviewed by the SEC), or if effectiveness is not maintained, the Company will incur liquidated damages payable to the Investors.
- Warrant Features: Warrants include cashless exercise provisions and adjustments for fundamental transactions.
Investor Verification Checklist
- Verify the net proceeds received after deducting the $1.1 million in fees and expenses.
- Confirm the filing date and status of the required Registration Statement (due within 30 days of Jan 25, 2013).
- Review the full text of the Securities Purchase Agreement and Registration Rights Agreement (Exhibits 10.1 and 10.2) for specific liquidated damage calculations.
- Assess the dilution impact of the 9.2 million shares issued and the 4.6 million shares underlying the warrants.